Orin Green Financial LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Orin Green Financial LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 306 shares of the company’s stock, valued at approximately $271,000.

Other institutional investors have also added to or reduced their stakes in the company. Abner Herrman & Brock LLC grew its holdings in Eli Lilly and Company by 1.4% during the first quarter. Abner Herrman & Brock LLC now owns 26,372 shares of the company’s stock valued at $20,517,000 after purchasing an additional 373 shares during the period. Rise Advisors LLC grew its holdings in Eli Lilly and Company by 112.3% during the first quarter. Rise Advisors LLC now owns 760 shares of the company’s stock valued at $592,000 after purchasing an additional 402 shares during the period. Farmers Trust Co. grew its holdings in Eli Lilly and Company by 19.3% during the first quarter. Farmers Trust Co. now owns 494 shares of the company’s stock valued at $384,000 after purchasing an additional 80 shares during the period. Foster Group Inc. grew its holdings in Eli Lilly and Company by 3.2% during the first quarter. Foster Group Inc. now owns 1,641 shares of the company’s stock valued at $1,277,000 after purchasing an additional 51 shares during the period. Finally, New Hampshire Trust grew its holdings in Eli Lilly and Company by 4.1% during the first quarter. New Hampshire Trust now owns 714 shares of the company’s stock valued at $555,000 after purchasing an additional 28 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE LLY traded up $6.41 during trading hours on Thursday, reaching $922.83. 458,889 shares of the stock traded hands, compared to its average volume of 2,979,211. The stock has a 50 day simple moving average of $919.25 and a two-hundred day simple moving average of $855.84. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The company has a market cap of $877.06 billion, a price-to-earnings ratio of 136.51, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. On average, analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Jefferies Financial Group raised their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Truist Financial raised their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Finally, BMO Capital Markets raised their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $986.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.